News headlines about Viveve Medical (NASDAQ:VIVE) have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viveve Medical earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.318339422584 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- $4.70 Million in Sales Expected for Viveve Medical (VIVE) This Quarter (americanbankingnews.com)
- -$0.42 EPS Expected for Viveve Medical (VIVE) This Quarter (americanbankingnews.com)
- What’s Ahead for Viveve Medical, Inc. (VIVE) After Reaching All-Time Low? (goldmanblog.com)
- An Eye on Profitability Ratios Viveve Medical, Inc. (VIVE) (nasdaqfortune.com)
Viveve Medical stock traded up $0.03 during trading hours on Monday, reaching $3.22. The company had a trading volume of 8,020 shares, compared to its average volume of 293,539. The company has a debt-to-equity ratio of -11.13, a current ratio of 3.41 and a quick ratio of 3.16. The stock has a market capitalization of $99.64, a P/E ratio of -1.53 and a beta of -0.48. Viveve Medical has a 12-month low of $3.12 and a 12-month high of $11.16.
VIVE has been the subject of a number of research analyst reports. ValuEngine upgraded Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Mizuho restated a “buy” rating on shares of Viveve Medical in a research report on Thursday, February 8th. Northland Securities began coverage on Viveve Medical in a research report on Friday, January 5th. They issued an “outperform” rating and a $8.00 target price for the company. Ladenburg Thalmann restated a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. Finally, Maxim Group restated a “buy” rating and issued a $11.00 target price on shares of Viveve Medical in a research report on Friday, March 16th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $10.00.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Viveve Medical (VIVE) Share Price” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3343500/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-viveve-medical-vive-share-price.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.